Media Articles Related to Ovrette (Norgestrel)
Many women seeking medical care have experienced reproductive coercion and intimate partner violence
Source: Pregnancy / Obstetrics News From Medical News Today [2014.03.01]
Enough women experience reproductive coercion - male behavior to control contraception and pregnancy outcomes - that a research team now recommends health care providers address the subjects with their patients and tailor family planning discussions and recommendations accordingly.
Research shows women trying hard to avoid unwanted pregnancy
Source: Abortion News From Medical News Today [2014.02.04]
Most women experiencing unwanted pregnancy report they used a contraceptive at the time they conceived, data released by the British Pregnancy Advisory Service (bpas) shows. Older women undergoing abortion were less likely to have used contraception than women under 30, which may reflect their belief they are no longer fertile.
Published Studies Related to Ovrette (Norgestrel)
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90
mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual
and premenstrual syndrome (PMS)... CONCLUSIONS: These data, although not consistent, indicate that continuous LNG/EE
Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. [2011.08]
BACKGROUND: Cytochrome P450 3 A is involved in ticagrelor and ethinyl oestradiol/levonorgestrel metabolism; so a potential drug-drug interaction may occur. OBJECTIVES: To assess: ticagrelor effects on ethinyl oestradiol/levonorgestrel pharmacokinetics, endogenous sex hormone levels; ethinyl oestradiol/levonorgestrel effects on ticagrelor pharmacokinetics; tolerability of ticagrelor + ethinyl oestradiol/levonorgestrel... CONCLUSIONS: Ticagrelor co-administration with ethinyl oestradiol/levonorgestrel increased ethinyl oestradiol exposure by approximately 20%, with no effect on levonorgestrel pharmacokinetics. No clinically relevant effect on contraceptive efficacy is expected with ethinyl oestradiol/levonorgestrel and ticagrelor co-administration.
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. [2011.03]
Use of oral contraceptives (OC) that combine a progestogen with synthetic ethinyl estradiol (EE) is associated with increased risk of venous thromboembolism. NOMAC/E2 is a new monophasic OC that combines nomegestrol acetate (NOMAC), a highly selective progestogen, with 17beta-estradiol (E2)...
A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. [2011.02]
OBJECTIVE: To compare the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) with that of a low-dose combined oral contraceptive (COC) in reducing fibroid-related menorrhagia... CONCLUSION: Although the rate of treatment failure was similar in both groups, the LNG-IUS was more effective in reducing MBL than the COC in women with fibroid-related menorrhagia. Copyright A(c) 2010 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. [2011.02]
OBJECTIVE: To compare the levonorgestrel intrauterine system (LNG-IUS) with hysterectomy in patients with adenomyosis and to study the effects of both treatments on quality of life (QOL)...
Clinical Trials Related to Ovrette (Norgestrel)
Hormone Therapy in Preventing Endometrial Carcinogenesis (Cancer) in Women With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer [Active, not recruiting]
RATIONALE: Hormone therapy may prevent the development of endometrial carcinogenesis (cancer)
in women with a genetic risk for hereditary nonpolyposis colon cancer. It is not yet known
which hormone therapy regimen is more effective in preventing endometrial cancer.
PURPOSE: Randomized phase II trial to compare two different hormone therapy regimens in
preventing endometrial cancer in women who have a genetic risk for hereditary nonpolyposis
A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA® (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST® (an Oral Contraceptive) [Completed]
A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA® (a Transdermal Contraceptive Patch) [Completed]
A Comparative Pharmacokinetic Study of ORTHO EVRA® (a Transdermal Contraceptive Patch) and CILEST® (an Oral Contraceptive) in Healthy Female Volunteers [Completed]
The objective of this study is to compare the levels of the hormones norelgestromin,
norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers
administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral
contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of
one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other
An Open-Label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol [Completed]